Titan Pharmaceuticals (NASDAQ:TTNP), founded in 1988 and headquartered in South San Francisco, is a clinical-stage biopharmaceutical company focused on the development and commercialization of sustained-release drug delivery systems. Its proprietary ProNeura® platform is designed to deliver therapeutic compounds consistently over extended periods—up to twelve months—addressing challenges associated with frequent dosing and patient adherence. This long-acting implant technology supports both small-molecule and peptide drugs, enabling more predictable pharmacokinetics and improved patient outcomes.
The company’s lead commercial product, Probuphine®, is a six-month subdermal implant for the treatment of opioid dependence. By continuously releasing buprenorphine, Probuphine aims to reduce the risk of diversion and misuse associated with daily dosing regimens. Titan originally secured U.S. regulatory approval for Probuphine in 2016 through a strategic partnership with Braeburn Pharmaceuticals, illustrating its collaborative approach to advancing clinical development, regulatory filings, manufacturing, and commercialization.
In addition to opioid dependence, Titan is advancing a pipeline of candidates targeting endocrine and neurological disorders, including Cushing’s disease and amyotrophic lateral sclerosis. All pipeline programs leverage the ProNeura platform to explore novel therapeutic applications and deliver candidates through preclinical and clinical stages. Titan has executed licensing and distribution agreements to broaden its geographic footprint, partnering with organizations in Europe, Asia, and Latin America to facilitate global development and market access.
Under the leadership of CEO Sunil Shah and a board comprising industry veterans in drug development and commercialization, Titan Pharmaceuticals remains committed to strategic partnerships and lean operations. The company’s R&D activities continue to be based in the San Francisco Bay Area, a leading biotechnology hub. With its focus on long-acting delivery technologies, Titan seeks to transform patient care by providing innovative, sustained-release therapies that meet unmet medical needs.
